ASCO 2026: Selpercatinib shows decrease in risk of disease recurrence or death as adjuvant therapy for early-stage RET fusion-positive NSCLC
Adjuvant treatment with the targeted therapy drug selpercatinib can help reduce the risk that cancer…
Browsing: Selpercatinib
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib for…
FDA approves selpercatinib for RET fusion-positive thyroid cancer
On June 12, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo,…
FDA grants accelerated approval to selpercatinib for paediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumours
On May 29, 2024, the Food and Drug Administration granted accelerated approval to selpercatinib (Retevmo,…
Researchers identify cryptic vulnerabilities in an oncoprotein
RET is a receptor protein with tyrosine kinase activity that can transfer a phosphate group…
AACR 2021: FDA-approved selpercatinib shows clinical benefits for RET fusion-positive cancers beyond lung and thyroid cancers
Clinical trial results of RET kinase inhibitor selpercatinib show that the targeted therapy was effective…
The Oncology Journal Club Episode 16
We’re back to our standard format for today’s episode of The Oncology Journal Club This…
Clinical trial of selpercatinib shows strong response for patients with non-small cell lung cancer
An international team of researchers has found that selpercatinib, a drug that precisely targets cancers…
Strong, durable responses to selpercatinib in RET-driven medullary thyroid cancer
Selpercatinib (Retevmo), a drug targeted precisely against cancers driven by mutations or alterations in the…